Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The cost-effectiveness of targeted or universal screening for vasa praevia at 18-20 weeks of gestation in Ontario.

Cipriano LE, Barth WH, Zaric GS. The cost-effectiveness of targeted or universal screening for vasa praevia at 18-20 weeks of gestation in Ontario. BJOG. 2010 Aug; 117(9):1108-18.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.